Navigation Links
SastoMed Starts Granulox Sales Today
Date:4/16/2012

WITTEN, Germany, April 16, 2012 /PRNewswire/ --

Subsequent to the granting of the CE mark authorizing production, distribution and sales in the member countries of the European Union, and after fifteen months of intensive strategic and operational preparation, global licensee SastoMed GmbH has initiated sales of Granulox today on the official approval of the first batch of products. Granulox, a spray aiming at improved healing of chronic wounds, is based on a patent by SanguiBioTech GmbH. It currently is the only therapeutic which can help to soothe the problem of hypoxia i.e. the lack of oxygen supply to chronic wounds. Indications as granted by the CE mark include diabetic foot, leg ulcer and decubitus ulcer.

"It is worth noticing", SastoMed Managing Director Michael Sander emphasized, "that thanks to our highly focused approach and diligent professional work we managed to obtain the CE mark ahead of our 2010 schedule but are fully prepared now for a head start into actual commercialization. This was our goal from the beginning and this first part of the mission was fully accomplished."

According to information provided by the joint venture company, SastoMed GmbH over the past months hired and trained a sales team of experienced wound management experts who will now take care of the German market. They will be supported by additional sales representatives. The sales team is focused on Granulox exclusively. In the course of premarketing activities multiple contacts among hospitals, wound ambulances and wound care practitioners have already been made aware of the advantages of Granulox. Based on the reaction by numerous experts, SastoMed, therefore, is pursuing ambitious sales targets and expects to having gained a 10% share of the market for modern wound treatment by the end of 2013.

The detailed marketing plan for the current year includes advertisement campaigns in specialized trade media, noticeable presence at key wound management conferences, congresses and medical trade fairs including booths, hosting of workshops and round table sessions as well as lectures and presentations, both in Germany and on an international level. Negotiations are underway with potential distributors in key European countries, SastoMed confirmed.

SastoMed also indicated that production capacity was contractually secured to meet demand beyond the current ambitious sales targets. Additional market assumptions and revenue expectations are to be disclosed at some later point in time after the launch phase of the sales initiatives.

SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc. (http://www.otcmarkets.com: SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:
Joachim Fleing
Phone: +49(160)741-27-17
Fax: +49(2302)915-191
e-mail: fleing@sangui.de


'/>"/>
SOURCE Sangui Bio Tech International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Introduces Global Innovation Starts Here Initiative to Foster Innovation and Quality Science
2. Mark Your Calendar - Open Enrollment for Medicare Prescription Drug and Health Plans Starts Earlier
3. Roche Starts Early Stage Clinical Trial in Down Syndrome
4. Prostate Cancer Awareness Month Starts in September
5. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
6. Sanofi Pasteur Starts Shipping Influenza Vaccine for the 2011-2012 Season
7. Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles)
8. Tibotec Starts Global Phase 3 Clinical Trials Studying TMC435 in Adults With Chronic Genotype 1 HCV
9. NovaShunt Starts its Pivotal Clinical Study "PIONEER" to Demonstrate the Clinical Value of the AFS System
10. Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
11. AMT Starts Development LPLChip(TM) With Progenika
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Research and Markets has announced the ... the USA"  report to their offering.  ,     (Logo: ... current Positron Emission Tomography (PET) scanner and cyclotron install ... Along with the current known number of PET scanners ... the report also contains a detailed breakdown of this ...
(Date:5/5/2016)... Research and Markets has announced the addition of the  "Market ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Emission Tomography (PET) scanner and cyclotron install base in the ... France , Germany , ... United Kingdom . Along with the current ...
(Date:5/5/2016)... May 5, 2016 ... addition of the  "Europe Thrombocythemia Market ...  report to their offering.  ... , ,The latest research Europe Thrombocythemia ... 2016, provides comprehensive insights into Thrombocythemia ...
Breaking Medicine Technology:
(Date:5/5/2016)... YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses Week ... job seeking nurses and healthcare employers. With their enrollment into the Talent Tech Lab ...
(Date:5/5/2016)... ... 05, 2016 , ... When stiff and achy joints are ... pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies point to ... , “Physical therapy exercises are commonly prescribed to individuals with osteoarthritis as ...
(Date:5/5/2016)... ... ... United Collection Bureau, Inc. (UCB) announces Sarah Clark as its new Vice President ... the healthcare revenue cycle industry. With a primary focus of end-to-end revenue cycle management, ... Spectrum Health. While at Spectrum Health, Clark helped Spectrum achieve the HFMA MAP Award ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a ... it can weaken the immune system and increase inflammation, both of which raise the ... the adult congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also ...
(Date:5/5/2016)... ... ... The Lung Institute will celebrate its three-year anniversary on May 14 by giving ... the month of May. To date, the Lung Institute has treated over 2,000 people at ... a testament to the success of this treatment and to the patients who refuse to ...
Breaking Medicine News(10 mins):